表紙
市場調查報告書
商品編碼
1043374

小兒克羅恩病 (pCD) (2030) 的流行病學和市場預測:初級研究(KOL 的見解)-市場情報

Pediatric Crohn's Disease (pCD)| Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast - 2030

出版日期: | 出版商: Mellalta Meets LLP | 英文 182 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

G7 國家的兒科克羅恩病市場預計在 2017 年將達到約 1.69 億美元,到 2030 年將達到 10 億美元。隨著下一代藥物進入市場,預計小兒克羅恩病市場將繼續增長。

小兒克羅恩病 (pCD) 的複發率非常高,因此儘管有目前的治療方法,但仍需要更有效的治療方法。新興藥物可能會解決當前的挑戰,並有望推動小兒克羅恩病的市場規模。人們還認為,降低兒童克羅恩病生物仿製藥的成本將促進市場競爭,有助於預算可持續性並改善患者獲得生物治療的機會。

本報告調查小兒克羅恩病 (pCD),並提供有關當前市場趨勢、G7 國家當前和預測病例、市場機會、競爭產品和 KOL 見解的信息。

示例

目錄

  • 執行摘要
  • 兒童克羅恩病的背景
  • 到 2030 年的流行病學估計和預測
    • 主要調查結果
    • 方法和數據源
      • 各國兒童克羅恩病患病率(美國、德國、法國、意大利、西班牙、英國和日本)
      • 治療小兒克羅恩病病例
    • 兒童克羅恩病流行病學和模型參數的主要來源
      • 美國
        • 小兒克羅恩病的患病率
        • 治療小兒克羅恩病病例
      • 德國
      • 法國
      • 意大利
      • 西班牙
      • 英國
      • 日本
  • 目前的治療和醫療實踐
    • 主要調查結果
    • 治療指南
  • 非處方治療章節
    • 阿達木單抗 (AbbVie/MedImmune)
    • 英夫利昔單抗(Janssen Biotech)
    • Pentasa(京林製藥/輝凌製藥)
  • 未滿足的需求
  • 新療法
    • 管道概覽
    • 兒科克羅恩病的治療開發管道
      • 產品分析
        • Mirikizumab(禮來公司)
        • Ustekinumab (Janssen Research & Development, LLC)
        • 維多珠單抗(武田腫瘤學)
        • Ozanimod(百時美施貴寶)
  • 新療法
      • 產品分析
        • STAT-201(Statera Biopharma, Inc. [原 Cytocom, Inc.)]
        • Etrolizumab (Genentech/Hoffmann-La Roche)
        • SGX203 (Soligenix Inc.)
        • CERC-002(Avalo Therapeutics, Inc.(原 Cerecor Inc.))
        • Alofisel(武田)
        • Thetanix(4d 製藥)
        • RBX-2660 (Rebiotix/Ferring)
  • 小兒克羅恩病費用負擔和處方調查
  • 未來治療範式
  • 當前和新療法的年度費用
  • 市場展望
    • 主要調查結果
    • 到 2030 年的國家市場預測
      • G7 小兒克羅恩病總市場(2020-2030,金額)
      • G7 小兒克羅恩病治療市場總量(2020-2030,金額)
  • 各國市場預測
    • 美國
      • 小兒克羅恩病市場(2020-2030,金額)
      • 按治療方法分類的小兒克羅恩病市場(2020-2030,金額)
    • 德國
    • 法國
    • 意大利
    • 西班牙
    • 英國
    • 日本
  • 市場促進和製約因素
  • 附錄
目錄
Product Code: MM202036

Despite the availability of current therapeutics, there remains the unmet need for more effective treatment to reduce the recurrence rate which is quite high. Emerging drugs like Mirikizumab (Eli Lilly and Company), Stelara (Janssen Research & Development, LLC), Entyvio(Takeda Oncology), and others are likely capable to eliminate the current challenges and also have the potential to drive the market size of pediatric Crohn's Disease (pCD). The reduced cost of biosimilars relative to Pediatric Crohn's disease can drive market competition, contributing to budget sustainability and improving patient access to biologic treatments.

Pediatric Crohn's Disease (pCD) is a rare condition commonly referred to as inflammatory bowel disease (IBD) which are immunologically mediated inflammatory diseases of the gastrointestinal tract occurring in children and adolescence. It typically affects the terminal ileum but can discontinuously affect the entire gastrointestinal tract and commonly leads to complications such as fistulas, abscesses, and stenosis. Although, there is no cure for Crohn's disease, but with proper treatment and support the disease can be effectively managed and may go into remission for long periods of time.

In long-term, pediatric Crohn's disease remains an attractive indication for drug development, with a rich clinical pipeline. Amid an increasingly competitive commercial landscape), we continue to view pediatric Crohn's disease as an attractive indication for drug development; no therapy in development has demonstrated 'game-changing' or meaningfully differentiated efficacy, leaving room for new entrants to compete. Among earlier-stage mechanisms, physicians indicate enthusiasm for additional safe, effective oral agents and may theoretically drive greater efficacy in select patient populations.

SAMPLE VIEW

Pediatric Crohn's Disease (pCD) - Prevalence (Epidemiology)

The diagnosis of Pediatric Crohn's Disease requires the integration of clinical presentation, laboratory tests, and endoscopic, histologic, pathologic and radiologic findings. In 2017, an expert panel, which included contributors from the Society of Abdominal Radiology Crohn's Disease-Focused Panel, the Society of Pediatric Radiology, and the American Gastroenterological Association, issued the guidelines on the use of computed tomography enterography (CTE) and magnetic resonance enterography (MRE) in patients with small bowel Crohn disease.

Pediatric Crohn's disease (pCD) is a rare, inflammatory bowel disease characterized by severe, chronic inflammation of the intestinal wall or any portion of the gastrointestinal tract. Crohn's Disease is most common in individuals between 15-35, with approximately 25% diagnosed by age 20. The total prevalent cases in the G7 countries are anticipated to rise from XX in 2017 to 82,519 by 2030 at a CAGR of 2.1% for the study period (2017-2030)"

Pediatric Crohn's Disease (pCD)- Current Market Size & Forecast Trends

The most widely used drugs in Crohn's Disease are corticosteroids, immunosuppressants, and biologicals (anti-TNF, anti-interleukins, and anti-integrins). The landscape of pediatric Crohn's disease (CD) is rapidly changing. Therapeutic advances seen in the adult arena are rapidly adopted by pediatric gastroenterologists and evaluated in both controlled studies and real-world experience. Additionally, pediatrics is leading the way as in a primary therapy which uses regimens including diet specific carbohydrate (SCD) and exclusive enteral nutrition (EEN). With the advent of the market entry of anticancer necrosis factor alpha (TNF-α) inhibitors, the market landscape has changed with more effective drugs with the potential for prolonged remission.

The pediatric Crohn's disease market is poised for continued growth as next-generation agents reach the market. The pediatric Crohn's disease market approached ~$169 million in sales in 2017 in G7 countries and expected to reach $1 Billion by 2030. Despite market growth, response rates to existing therapies remain suboptimal, and patients often lose response over time; as a result, patients commonly cycle through multiple chronic therapies. The propensity for patients to cycle through therapies enables new entrants to garner share and supports several therapeutic classes; among near-term entrants, we expect oral S1P receptor modulators, and IL-23 mAbs may all achieve blockbuster class sales. The primary drivers of this growth will be the uptake of the emerging drugs i.e., Mirikizumab (Eli Lilly), SGX203 (Soligenix ), STAT-201 (Statera Biopharma) and others.

SAMPLE VIEW

Report Highlights:

  • Pediatric Crohn's Disease (pCD)- Current Market Trends
  • Pediatric Crohn's Disease (pCD)- Current & Forecasted Cases across the G7 Countries
  • Pediatric Crohn's Disease (pCD)- Market Opportunities and Sales Potential for Agents
  • Pediatric Crohn's Disease (pCD)- Patient-based Market Forecast to 2030
  • Pediatric Crohn's Disease (pCD)- Untapped Business Opportunities
  • Pediatric Crohn's Disease (pCD)- Product Positioning Vis-a-vis Competitors' Products
  • Pediatric Crohn's Disease (pCD)- KOLs Insight

Table of Contents

  • Executive Summary
    • Key Findings
    • Pediatric Crohn's Disease: Current and Emerging Trends
  • Pediatric Crohn's Disease Background
    • Pediatric Crohn's disease Definition
    • Signs and Symptoms
    • Causes
    • Pathophysiology
    • Diagnosis
  • Epidemiology Estimated and Forecast to 2030
    • Key Findings
    • Methods and data Sources
      • Country Specific Prevalent Cases of Pediatric Crohn's Disease (US, Germany, France, Italy, Spain, UK, and Japan)
      • Country Specific Treated Cases of Pediatric Crohn's disease by Therapies
    • Key Sources for Pediatric Crohn's disease Epidemiology and Model Parameters
      • United States
        • United States Prevalent cases of Pediatric Crohn's disease
        • United States Treated Cases of Pediatric Crohn's disease by Therapies
      • Germany
        • Germany Prevalent cases of Pediatric Crohn's disease
        • Germany Treated Cases of Pediatric Crohn's disease by Therapies
      • France
        • France Prevalent cases of Pediatric Crohn's disease
        • France Treated Cases of Pediatric Crohn's disease by Therapies
      • Italy
        • Italy Prevalent cases of Pediatric Crohn's disease
        • Italy Treated Cases of Pediatric Crohn's disease by Therapies
      • Spain
        • Spain Prevalent cases of Pediatric Crohn's disease
        • Spain Treated Cases of Pediatric Crohn's disease by Therapies
      • United Kingdom
        • United Kingdom Prevalent cases of Pediatric Crohn's disease
        • United Kingdom Treated Cases of Pediatric Crohn's disease by Therapies
      • Japan
        • Japan Prevalent cases of Pediatric Crohn's disease
        • Japan Treated Cases of Pediatric Crohn's disease by Therapies
  • Current Therapies and Medical Practice
    • Key Findings
    • Treatment Guidelines
  • Marketed Therapies Chapters
    • Adalimumab (AbbVie/MedImmune)
    • Infliximab (Janssen Biotech)
    • Pentasa (Kyorin Pharmaceutical/Ferring Pharmaceuticals)-
  • Unmet Needs
  • Emerging Therapies
    • Pipeline Overview
    • Therapeutic Developments Pipeline for Pediatric Crohn's Disease
      • Product Analysis
        • Mirikizumab (Eli Lilly and Company)
          • Product Profile
          • Clinical Development
          • Sales & Market Opportunity by 2030
        • Ustekinumab (Janssen Research & Development, LLC)
          • Product Profile
          • Clinical Development
          • Sales & Market Opportunity by 2030
        • Vedolizumab (Takeda Oncology)
          • Product Profile
          • Clinical Development
          • Sales & Market Opportunity by 2030
        • Ozanimod (Bristol Myers Squibb)
          • Product Profile
          • Clinical Development
          • Sales & Market Opportunity by 2030
  • Emerging Therapies
      • Product Analysis
        • STAT-201 (Statera Biopharma, Inc. [Formerly Cytocom, Inc.)]
          • Product Profile
          • Clinical Development
          • Sales & Market Opportunity by 2030
        • Etrolizumab (Genentech/Hoffmann-La Roche)
          • Product Profile
          • Clinical Development
          • Sales & Market Opportunity by 2030
        • SGX203 (Soligenix Inc.)
          • Product Profile
          • Clinical Development
          • Sales & Market Opportunity by 2030
        • CERC-002 (Avalo Therapeutics, Inc. (Formerly Cerecor Inc.))
          • Product Profile
          • Clinical Development
          • Sales & Market Opportunity by 2030
        • Alofisel (Takeda)
          • Product Profile
          • Clinical Development
        • Thetanix (4d pharma)
          • Product Profile
          • Clinical Development
        • RBX-2660 (Rebiotix/Ferring)
          • Product Profile
          • Clinical Development
  • Pediatric Crohn's Disease- Cost Burden & Prescriptions survey
  • Future Treatment Paradigm
    • Pediatric Crohn's Disease Competitor Landscape and Approvals Anticipated
    • Future Treatment Algorithms and Competitor Positioning
    • Key Data Summary for Emerging Treatment
  • Annual Cost of Current & Emerging Therapies
  • Market Outlook
    • Key Findings
    • Country Specific Market Forecast to 2030
      • G7 total Market for Pediatric Crohn's Disease 2020-2030 (USD Million)
      • G7 total Market for Pediatric Crohn's Disease by Therapies 2020-2030 (USD Million)
  • Market Forecast by Country
    • United States
      • United States Market for Pediatric Crohn's Disease 2020-2030 (USD Million)
      • United States Market for Pediatric Crohn's Disease by Therapies 2020-2030 (USD Million)
    • Germany
      • Germany Market for Pediatric Crohn's Disease 2020-2030 (USD Million)
      • Germany Market for Pediatric Crohn's Disease by Therapies 2020-2030 (USD Million)
    • France
      • France Market for Pediatric Crohn's Disease 2020-2030 (USD Million)
      • France Market for Pediatric Crohn's Disease by Therapies 2020-2030 (USD Million)
    • Italy
      • Italy Market for Pediatric Crohn's Disease 2020-2030 (USD Million)
      • Italy Market for Pediatric Crohn's Disease by Therapies 2020-2030 (USD Million)
    • Spain
      • Spain Market for Pediatric Crohn's Disease 2020-2030 (USD Million)
      • Spain Market for Pediatric Crohn's Disease by Therapies 2020-2030 (USD Million)
    • United Kingdom
      • United Kingdom Market for Pediatric Crohn's Disease 2020-2030 (USD Million)
      • United Kingdom Market for Pediatric Crohn's Disease by Therapies 2020-2030 (USD Million)
    • Japan
      • Japan Market for Pediatric Crohn's Disease 2020-2030 (USD Million)
      • Japan Market for Pediatric Crohn's Disease by Therapies 2020-2030 (USD Million)
  • Market Drivers and Constraints
    • What Factors Are Driving the Market for Pediatric Crohn's Disease?
    • What Factors Are Constraining the Market for Pediatric Crohn's Disease?
  • Appendix